Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-56286 (Emrusolmin) Open-Label Extension in Multiple System Atrophy
NCT07197866Phase 2Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of emrusolmin in multiple system atrophy (MSA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Number of participants experiencing an adverse event at 100 weeks and Number of participants who withdrew from the trial due to an adverse event at 100 weeks. Started Sep 2025; status: recruiting.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07197866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197866.